| Xu, Ruihua |
JUPITER-02, NCT03581786: The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer |
|
|
| Active, not recruiting | 3 | 289 | RoW | TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy, Placebos | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic NPC | 05/20 | 10/22 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 3 | 514 | RoW | Toripalimab, JS001, TAB001 | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy | 03/21 | 09/23 | | |
|
|
|
|
|
|
|
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
FRUTIGA, NCT03223376: A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer |
|
|
| Active, not recruiting | 3 | 703 | RoW | fruquintinib +paclitaxel, HMPL-013+paclitaxel, fruquintinib placebo + paclitaxel, HMPL-013 placebo+paclitaxel | Hutchison Medipharma Limited, Sun Yat-sen University | Advanced Gastric Cancer | 09/22 | 11/22 | | |
|
|
|
|
CLASSIC, NCT04262635: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 3 | 80 | RoW | Cetuximab, Capecitabine, Cetuximab | Sun Yat-sen University | Colorectal Cancer | 12/22 | 08/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06296706: A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Recruiting | 3 | 630 | RoW | Docetaxel for injection (Albumin-bound), HB1801, Taxotere (docetaxel), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Cancer | 06/26 | 06/27 | | |
NCT06501664: Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC |
|
|
| Not yet recruiting | 3 | 360 | NA | liposomal irinotecan, Nal-IRI, 5-FU, Fluorouracil, LV, Calcium folinate, Irinotecan, IRI | Rui-hua Xu, MD, PhD | Esophageal Cancer | 11/26 | 11/27 | | |
NCT06640361: A Study of Olverembatinib in SDH-deficient GIST. |
|
|
| Not yet recruiting | 3 | 40 | RoW | Olverembatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | GIST | 03/27 | 06/29 | | |
HA1818-008, NCT06656091: A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 3 | 450 | NA | simmitinib, investigator's choice of chemotherapy,include docetaxel or irinotecan. | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Advanced Oesophageal Squamous Cell Carcinoma | 01/27 | 01/27 | | |
SHR-A1904-302, NCT06649292: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 524 | RoW | SHR-A1904, Paclitaxel, Docetaxel, Irinotecan | Shanghai Hengrui Pharmaceutical Co., Ltd. | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 09/27 | 03/28 | | |
NCT06022861: A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 510 | RoW | LY01015, Fluorouracil, Cisplatin, Opdivo® | Shandong Boan Biotechnology Co., Ltd | Esophageal Squamous Cell Carcinoma | 06/25 | 12/26 | | |
NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation |
|
|
| Recruiting | 3 | 776 | RoW | FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation | Sun Yat-sen University | Rectal Cancer | 09/25 | 09/28 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NOTABLE-307, NCT05978050: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 354 | RoW | nimotuzumab plus paclitaxel, Combined with chemotherapy, placebo plus paclitaxel, chemotherapy alone | Biotech Pharmaceutical Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 03/26 | 03/26 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
CIBI310L301, NCT05890742: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer |
|
|
| Recruiting | 3 | 360 | RoW | Sintilimab, IBI310&Sintilimab, Radical surgery | Innovent Biologics (Suzhou) Co. Ltd. | MSI-H | 04/28 | 07/28 | | |
| Recruiting | 2/3 | 439 | RoW | SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Metastatic Colorectal Cancer (mCRC) | 11/22 | 11/24 | | |
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) |
|
|
| Recruiting | 2/3 | 568 | Japan, RoW | HLX10, serplulimab, HLX04、, Bevacizumab | Shanghai Henlius Biotech | Metastatic Colorectal Cancer | 09/25 | 12/26 | | |
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2/3 | 606 | RoW | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab | Jiangsu HengRui Medicine Co., Ltd. | Colorectal Cancer | 12/25 | 12/26 | | |
NCT04724239: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Sintilimab, Chidamide, IBI305, Bevacizumab | Sun Yat-sen University | Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer | 07/22 | 12/23 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05705635: A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Docetaxel for injection (Albumin-bound), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction | 05/23 | 12/24 | | |
NCT05117658: Study of HA121-28 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 83 | RoW | HA121-28 tablet | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NSCLC | 10/23 | 10/23 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
| Recruiting | 2 | 23 | RoW | Dostarlimab, GSK4057190A, TSR-042 | GlaxoSmithKline | Neoplasms, Rectal | 12/28 | 03/31 | | |
NCT05962502: Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy |
|
|
| Recruiting | 2 | 54 | RoW | Cetuximab and irinotecan, ERBITUX | Sun Yat-sen University | Metastatic Colorectal Cancer | 03/25 | 12/26 | | |
| Active, not recruiting | 2 | 114 | RoW | Paclitaxel, Cisplatin, Taxol, tislelizumab, Radiotherapy, intensity-modulated radiotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Jieyang People's Hospital | Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | 11/25 | 07/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
| Active, not recruiting | 1/2 | 401 | RoW | 3 mg/kg anti-PD-1 mAb JS001 Q2W, toripalimab, TAB001, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma | 02/20 | 04/22 | | |
|
|
|
|
|
|
|
|
| Completed | 1/2 | 81 | RoW | SHR-1701；BP102 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 03/24 | 03/24 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06376136: A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | BAT8010 for Injection, BAT1006 for Injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/26 | | |
NCT05745623: A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors |
|
|
| Recruiting | 1/2 | 55 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | 06/24 | 12/26 | | |
NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | MRG003+HX008 | Shanghai Miracogen Inc. | Advanced Solid Tumors | 05/25 | 07/25 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT05877651: MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. |
|
|
| Completed | 1 | 22 | RoW | MASCT-I injection | SYZ Cell Therapy Co.. | Solid Tumors | 10/21 | 10/21 | | |
NCT05015309: A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor |
|
|
| Not yet recruiting | 1 | 40 | RoW | SH3765 tablet | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Advanced Malignant Tumor | 03/23 | 09/24 | | |
| Recruiting | 1 | 60 | RoW | TQB2930 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancers | 04/23 | 12/23 | | |
NCT03544905: Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 |
|
|
| Recruiting | 1 | 100 | RoW | CYH33 for tablet | Haihe Biopharma Co., Ltd. | Advanced Solid Tumors | 06/23 | 03/24 | | |
MASCT-I, NCT03034304: A Phase I Clinical Study for Evaluating the Safety and Efficacy of in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 193 | RoW | MASCT-I, Ifosfamide, PD1 antibody, Adriamycin, Gemcitabine, Cisplatin, Carboplatin | SYZ Cell Therapy Co.. | Advanced Solid Tumors | 07/23 | 07/23 | | |
NCT04991129: The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer |
|
|
| Recruiting | 1 | 66 | RoW | WJ01024 | Suzhou Junjing BioSciences Co., Ltd. | Advanced Hematologic Malignancies, Advanced Solid Tumors | 06/25 | 04/26 | | |
NCT05061628: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor |
|
|
| Recruiting | 1 | 176 | RoW | JS006 as Monotherapy, JS006 in combination with Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Tumors | 08/23 | 09/24 | | |
| Recruiting | 1 | 94 | RoW | SHR-A1904 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Cancer | 10/23 | 01/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
NCT05751486: A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 1 | 24 | RoW | Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001 | Shanghai Junshi Bioscience Co., Ltd. | Advanced Nasopharyngeal Carcinoma | 12/23 | 12/25 | | |
| Recruiting | 1 | 270 | RoW | NBL-028 | NovaRock Biotherapeutics, Ltd | Advanced Solid Tumor | 01/27 | 01/27 | | |
| Not yet recruiting | 1 | 71 | RoW | TQB2102 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 04/24 | 10/24 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | Canada, US, RoW | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
| Recruiting | 1 | 924 | RoW | SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab | Shanghai Hengrui Pharmaceutical Co., Ltd. | Cldn18.2-positive Advanced Solid Tumor | 12/27 | 12/28 | | |
NCT05385692: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1 | 24 | RoW | AMT-676 | Multitude Therapeutics Inc. | Advanced Solid Tumors | 10/25 | 02/26 | | |
NCT05690581: Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies |
|
|
| Recruiting | 1 | 146 | RoW | CM369 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors and Hematologic Malignancies | 06/24 | 04/25 | | |
NCT05867303: A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 48 | RoW | RC198 Injection | RemeGen Co., Ltd. | Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma | 09/24 | 12/24 | | |
BL-M17D1-102, NCT06500052: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Solid Tumor | 08/26 | 08/26 | | |
NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 118 | RoW | JS107, Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Solid Tumors | 07/24 | 12/24 | | |
NCT06571422: Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 93 | RoW | WJ47156, JS001+Bevacizumab, Toripaliman injection+Bevacizumab Injection | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Advanced Malignant Solid Tumors | 05/26 | 04/27 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT05781386: A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors |
|
|
| Recruiting | 1 | 255 | RoW | SIM1811-03 or in combination with Sintilimab injectiont | Jiangsu Simcere Biologics Co., Ltd | Advanced Solid Tumor, Cutaneous T Cell Lymphoma | 06/25 | 12/25 | | |
NCT05979155: A Study of NWY001 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 196 | RoW | NWY001 | Chipscreen Biosciences, Ltd. | Advanced Solid Tumor | 01/26 | 05/28 | | |
NCT06094556: An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 240 | RoW | SHR-1826 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 06/27 | 07/27 | | |
| Completed | N/A | 210 | RoW | Breathing test | Mian XI | Esophageal Squamous Cell Carcinoma | 10/23 | 11/23 | | |
| Xu, RH |
| No trials found |
